

THE AMERICAN SOCIETY OF HEMATOLOGY

Annual Meeting

BLOOD, 56, 1, 59a, 1985.

Person to whom all correspondence and notification regarding this abstract should be addressed:

Name Dr. Alexander E. Felice

Address Medical College of Georgia  
Augusta, GA 30912-3331

Phone Number (404) 724-5116, Extension 2457

Mail to: National Office  
 American Society of Hematology  
 Abstract Division  
 6900 Grove Rd.  
 Thorofare, New Jersey 08086

**DO NOT FOLD!**

Indicate membership:

- American Society of Hematology  
 Council on Thrombosis

Please read abstract carefully before mailing. An additional charge of \$15 will be assessed for all editorial corrections (consult accompanying Rules).

Check Appropriate Category

- Red Cell Structure & Function
- Anemias
- Hemoglobinopathies and Thalassemias
- Hematopoietic Cell Proliferation and Differentiation
- Hematopoietic Growth Factors
- Granulocytes and Monocytes
- Lymphocytes
- Bone Marrow Failure
- Molecular Oncology
- Leukemias and Myeloproliferative Disorders
- Lymphomas and Plasma Cell Dyscrasias
- Immunohematology
- Transfusion
- Coagulation and Thrombosis
- Platelets
- Bone Marrow Transplantation

TYPE ABSTRACT HERE

DEVELOPMENTAL HEMATOLOGY OF SS AND SC DISEASE IN ASSOCIATION WITH  $\alpha$ -THALASSEMIA-2. A.E. Felice, E.M. Marino\*, K.M. McKie\*, and V.C. McKie\*. Comprehensive Sickle Cell Center, Departments of Cell and Molecular Biology and Pediatrics, Medical College of Georgia, Augusta, GA.

The number and organization of the  $\alpha$ ,  $\zeta$  and  $\gamma$  globin genes have been determined on the DNA of 400 patients attending the Pediatric Sickle Cell Clinics of our Center. The patients were participating in long-term prospective studies on possible effects of  $\alpha$ -thal on the hematological changes accompanying postnatal development. CBC and Hb composition were obtained in the steady state on patients of different ages and correlated with the number of  $\alpha$  globin genes. All patients included in this study had SS or SC, and normal  $\gamma$  and  $\zeta$  genes but differed in the number of  $\alpha$  genes due to normal  $\alpha$  genotypes ( $\alpha\alpha/\alpha\alpha$ );  $\alpha$ -thal-2 heterozygosity ( $-\alpha/\alpha\alpha$ ); and homozygosity ( $-\alpha/-\alpha$ ). The type I or type II, -3.7 Kb  $\alpha$ -thal-2 had the following gene frequencies; SS: 0.18; SC: 0.19. Neither the -4.2 Kb  $\alpha$ -thal-2, nor the type III -3.7 Kb  $\alpha$ -thal-2 have been observed in our patients. For both SS and SC patients, the gene frequency was invariant in the first two decades of life. Hematological analyses revealed complex interactions between  $\alpha$ -thal, Hb F and development among SS but not SC patients. Although the MCV and RBC values of both SS and SC children gave the expected microcytosis and erythrocytosis due to  $\alpha$ -thal, the Hb levels of the SS patients with  $\alpha\alpha/\alpha\alpha$ ,  $-\alpha/\alpha\alpha$  or  $-\alpha/-\alpha$  were the same up to the age of 5 to 7 yrs. Older children with SS  $-\alpha/-\alpha$  had higher Hb levels than the SS  $-\alpha/\alpha\alpha$  which in turn were higher than those of the SS  $\alpha\alpha/\alpha\alpha$ . This difference emerged only after the proportion of Hb F declined to levels under 15%. The Hb F levels of the SS patients with 4, 3, or 2  $\alpha$  genes were similar after 7 yrs while for the SC patients, the values were similar after 3 yrs. The MCHC of the SS;  $\alpha\alpha/\alpha\alpha$  patients under 5 yrs of age could be as low as that of the SS  $-\alpha/\alpha\alpha$  or SS;  $-\alpha/-\alpha$ . This might be due to asynchronous development of the MCH and MCV values in young children with SS and different numbers of  $\alpha$  globin genes.

The submission fee is \$25. Make checks payable to the American Society of Hematology.

Abstracts of work that has been published or presented at a national meeting prior to December 1, 1985 will not be accepted for the program or, if accepted, will not be presented. If similar work has been published or presented the original features of this study should be outlined in the covering letter.

The material in this abstract will have been presented at a national meeting or published as a full paper prior to December 1, 1985.

Yes  No

If accepted for a poster session.  
 I would present  
 I would not present

Member's signature   
 (each member may sponsor two abstracts)

3/2

37